Immunovant halts lupus program after Phase 2b trial fails to meet efficacy endpoints

Immunovant announced that its anti‑FcRn drug imeroprubart (IMVT‑1402) did not achieve the primary endpoint in a Phase 2b study in patients with cutaneous lupus erythematosus.

The double‑blind trial enrolled 57 adults who received the drug or placebo for 12 weeks, and the change in disease‑activity score at week 12 failed to show a statistically significant improvement.

While the company will discontinue the lupus program, it said the asset remains under investigation for potential uses in neurology, endocrinology and rheumatology.

Analysts viewed the lupus indication as low priority and the setback is unlikely to affect the broader pipeline, though the negative readout underscores the challenges of targeting FcRn in autoimmune disease.